Great company, bad stock

Article Abstract:

Genentech and Amgen are among 40 biotech companies, which have remained independent and reached the sales and market value heights of top pharmaceutical makers. Genentech, however, is far from a great stock, as the problem for investors willing to pay for a premium for Genentech is that the stock price reflect future earnings growth and a high multiple that there is limited room to improve and greater risk of disappointment.

Pharmaceutical preparations, Securities issued, listed, Pharmaceutical industry, Biological products industry, Securities, Genentech Inc., Amgen Inc., AMGN, Company securities, DNA

---

Time to kick that drug habit

Article Abstract:

Biopharmaceuticals are always known to come out in headlines, venture capital, and investor passion whereas diagnostics are not a high-margin business like biopharmaceuticals. However, there are companies that benefit from diagnostic companies as they make, distribute and service products with more genetic testing and analysis component, and provide stability and reliability.

Production management

---

Bugs or drugs, tortoises or hares?

Article Abstract:

The biotech enzyme and microorganism world offers the opportunity of steady annual return for ten years with lower risk of loss. But there are few exceptions, investing in a biotech drugmaker which means they have to wait for 10 years or more for a first drug and then, if the drug is approved and successful, they would enjoy some nice returns.

Analysis, Return on investment, Rate of return

Similar abstracts:

• Abstracts: Korean biotechs seize opportunity to list on public markets. Swiss patent proposal prompts criticism
• Abstracts: New biotech oasis? Spanish wishful thinking towards biotech. BioXell: An Italian Biotech success story?
• Abstracts: Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Hot spot MRI emerges from the background
• Abstracts: Shift toward early-stage deals favors bioteochs. Public biotech 2006- the numbers
• Abstracts: Liberty link rice raises specter of tightened regulations. Nanomedicine lacks recognition in Europe. UK seeks to relax shareholder preemption rights

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.